Currently Viewing:
The Academy of Managed Care Pharmacy (AMCP) Nexus 2018
Drug Market to See More Competition, Launch of Biosimilars in 2019
October 23, 2018
Currently Reading
Dr Aimee Tharaldson Outlines Current Key Market Trends in Specialty Pharmacy
October 23, 2018
Law to Curb Opioid Abuse Will Have Many Managed Care Priorities, Experts Say
October 23, 2018
Analysis Finds HIV Therapy Biktarvy Associated With Cost Savings Compared With Most Regimens
October 24, 2018
Dr Christopher Diehl Explains the Pharmacist's Role in Value-Based Models
October 24, 2018
Dr Jennifer Graff on Using Real-World Evidence to Deliver High-Quality Care
October 24, 2018
CMS Audits Give View Into How Well Health Plans Deliver Medicare Programs
October 24, 2018
Massachusetts Medicaid Finds CAR T-Cell Payment Solution While Waiting on CMS
October 25, 2018
Dan Mendelson: Healthcare Policy Changes Avalere Health Is Paying Attention To
October 25, 2018
Dr Kibum Kim on Precision Medicine in Managed Care
October 25, 2018
From Pathways to Pharmacy: Sharing Approaches to Value-Based Care
October 25, 2018
Dr Jane F. Barlow on How Curative, High-Cost Therapies Will Affect Patient OOP Costs
November 09, 2018
Dr Aimee Tharaldson: Recently Approved Specialty Drugs, Upcoming Approvals to Watch For
November 13, 2018
Dan Mendelson Discusses How Mergers and Acquisitions Are Affecting the Market
November 14, 2018
Dan Mendelson on the Trump Administration's Efforts to Lower Drug Prices
November 22, 2018
Dr Jane F. Barlow Discusses Potential New Reimbursement Models for New, High-Cost Therapies
November 27, 2018
Dan Mendelson's Expectations for Cross-Sector Mergers Like CVS, Aetna
November 28, 2018
Specialty Drug Approvals Dr Aimee Tharaldson is Looking Out for in 2019
November 29, 2018
Dan Mendelson on the Shift to Value-Based Care and Prescribing Patterns
December 22, 2018

Dr Aimee Tharaldson Outlines Current Key Market Trends in Specialty Pharmacy

Current key market trends include biosimilar, cancer, and orphan drug approvals, explained Aimee Tharaldson, PharmD, a senior clinical consultant in Emerging Therapeutics for Express Scripts.


Current key market trends include biosimilar, cancer, and orphan drug approvals, explained Aimee Tharaldson, PharmD, a senior clinical consultant in Emerging Therapeutics for Express Scripts.

Transcript

What are some current key market trends in specialty pharmacy?

We’re definitely seeing more approved. So far, 12 biosimilars have been approved, but only 6 of them launched. So, patent litigation is sometimes tying up the actual launch of these products, but we could have 8 more biosimilars approved by the end of the year. So, that’s obviously creating more competition within some of these therapy classes. We’re probably going to have to wait until 2023 before biosimilars to Humira launch, but several other biosimilars including some new cancer biosimilars like Avastin and Herceptin biosimilars will be launched next year. We already have Neulasta and Neupogen biosimilars on the market, so, that’s one area.

We’re also seeing a lot of development for cancer medications. Last year, we had 15 new cancer drugs approved, this year we’ve already had 12 with 4 more that are pending approval. So, we’re seeing a lot of new therapies for cancer. Often time, these are niche patient populations. Many of these are targeted therapies with specific pharmacogenetic testing to identify appropriate patients for therapy. And a lot of these are breakthrough therapies too, so they’re getting to market very quickly.

And then another market trend would be orphan drug development. So these are medications that treat less than 200,000 patients in the United States. Manufacturers are given 7 years exclusivity and some incentives for their development. But in all, there are about 30 million orphan diseases affecting Americans, so it’s very large when you look at it as a group of different orphan conditions.

Many of these orphan drugs become blockbusters—so, annual sales greater than a billion dollars—because they’re so high cost. So, we’re seeing a lot of development focused there. When you look at the specialty pipeline, about 45% of all specialty drugs in development are for orphan conditions. When you bring in cancer, too, that makes them about two-thirds of the pipeline. So, that’s definitely where the market is focused at this point. We’ve had 10 new orphan drugs approved so far this year.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up